 Can-Fite BioPharma Ltd NYSE: CANF has signed a development and commercialization agreement with France-based veterinary biotech company, Vetbiolix, to develop Piclidenoson to treat osteoarthritis in companion animals. Vetbiolix will have the exclusive right to Piclidenoson in the veterinary osteoarthritis market for two years, during which it will conduct proof-of-concept studies and cover all associated costs. 